Programmed cell death protein-1 (PD-1) inhibitors that have been recently introduced for the systemic treatment of head and neck cancers offer the advantage of fewer side effects and more effective treatment than chemotherapy drugs. A review of the literature shows that the ototoxic side effects of the PD-1 inhibitor have not yet been fully elucidated. In this study, we aimed to investigate whether the PD-1 inhibitor has ototoxic activity using both electrophysiological and histopathological methods.
A total of 24 rats, 12 for the study group, and 12 for the control group were included in the study. The study group was administered the PD-1 inhibitor. The auditory brainstem responses (ABR) of the study and control groups were evaluated. At the end of the study, all animals were sacrificed, and their cochleae were examined by immunohistochemical staining.
In the study group, the ABR values were 13.95 ± 2.70 before treatment, 15.83 ± 1.94 at week 4 of treatment (p=0.024), and 15.00 ± 1.06 at week 7 (p=0.157). Furthermore, according to immunohistochemical staining, the cochlear hair cells were reduced in the study group compared to the control group.
It was determined that the PD-1 inhibitor showed ototoxic activity during the course of treatment, but this was spontaneously resolved during follow-up. The clinical significance of these findings should be supported by human studies.
Squamous cell carcinoma of the head and neck (SCCHN) is a malignancy that causes more than 300,000 deaths worldwide every year. SCCHN treatment usually requires a multidisciplinary approach involving surgery, radiotherapy, and systemic medical therapy .
Advancements in systemic treatment modalities have led to the development of programmed cell death protein-1 (PD-1) inhibitors that have the advantages of being more effective in appropriate indications and offering a more comfortable treatment with fewer side effects compared to chemotherapy drugs [1-3]. Pembrolizumab is a monoclonal antibody that is present in T and pro-B cells and targets PD-1. Clinically, PD-1 blockade elicits strong antitumor immune responses. Antibodies that block PD-1 ligation, such as pembrolizumab, have recently been introduced in the treatment of SCCHN, non-small cell lung cancer, kidney cell cancer, and melanoma . In patients with SCCHN, the side effects of pembrolizumab therapy have been reported as fatigue, pruritus, rash, diarrhea, elevated liver function, hyponatremia, heart failure, hypothyroidism, adrenal insufficiency, and myositis .
Our review of the literature showed that the ototoxic side effects of pembrolizumab are not yet clearly known [6, 7]. Therefore, in this study, we investigated whether pembrolizumab has ototoxic activity based on both electrophysiological auditory brainstem responses (ABR) and histopathological data. In addition, using histopathological findings, we aimed to find an answer to the question of which part of the inner ear this possible ototoxic activity involves.
Materials & Methods
The animal experiments were commenced after the approval of the local ethics committee (protocol number 0046). Twenty-four 10-12-week-old brown rats (Rattus norvegicus) weighing 250-400 g were included in the study. The study and control groups each consisted of 12 animals, six males, and six females. Microscopic examination was performed on all subjects on day 0 (before treatment) under general anesthesia (Zeiss, OPMI 9, Germany), and rats which after examination showed natural ears were included in the study while those with tympanic membrane rupture and external auditory canal pathology were excluded. If present, the earwax plug of the rats in the outer ear was cleaned. Then, the ABR test (Eclipse 25 ABR System, Interacoustic, Denmark) was performed on the right and left ears of all rats before treatment, and the results were recorded.
Electrodes were placed as follows: ground line on the lower part of the forehead, positive line on the upper part of the forehead, one negative electrode to left ear mastoid and the other negative electrode to the right ear mastoid. In the course of the test, attention was paid to keep cables away from the recording device to the extent reasonably practice, in a separated manner and effort was made to maintain electrode-skin impedances below 5kΩ. All the animals included in the study were found to have normal ABR values before the treatment.
No treatment was applied to the control group. The study group was administered 2 mg/kg intravenous PD-1 inhibitor (BioXCell, West Lebanon, New Hampshire) through the tail of the animals twice at three-week intervals . The study group received PD-1 on day 0 and at week 3, and one week after each treatment session, the ABR test was performed on both ears of the animals. After the last PD-1 injection, the animals were followed up for one month, and the final ABR test was conducted at week 7. All animals were subjected to the ABR test four times in total: day 0 (before the treatment for the study group), week 1, week 4, and week 7. At the seventh week of the study, when the last ABR was undertaken, all animals were sacrificed, and the right and left inner ear auditory region (cochlear hair cells) of each rat was histopathologically evaluated.
The cochlea of each rat was kept in the fixator at 4° C for 24 hours in a 10% formaldehyde solution. The cochlea was then calcined with 10% ethylenediaminetetraacetic acid disodium salt dihydrate (pH 7.0; Muto Pure Chemicals, Tokyo, Japan) for two days at room temperature. The cochlea was dehydrated with a graduated ethanol sequence and xylene, embedded in paraffin and then cut at 3.0 µm in a midmodular plane [9, 10]. Slides containing the cochlea segments were stained with hematoxylin-eosin (H-E) (hematoxylin from Muto Pure Chemicals; eosin from Wako Pure Chemicals Industries, Osaka, Japan) to examine the structure. The samples were divided into three half-turns (basal, upper basal, apical) with a laboratory microscope (BX51; Olympus, Tokyo, Japan). Cochlear samples were photographed with a BZ-8100 light microscope. The specimens were examined by a single pathologist who was blind to the study and control groups. In histopathological evaluation, the loss of outer hair cell was evaluated as follows; 0, no degeneration (0% to 25% loss of external hair cells); +, slight degeneration (26% - 50% loss of external hair cells); ++, moderate degeneration (51% to 75% hair cell loss); and +++, severe degeneration (76% to 100% hair cell loss) .
Data were statistically analyzed using SPSS 21 (SPSS, Inc., IBM Company, Chicago, IL, USA). The results are presented as descriptive statistics (mean ± standard deviation [SD], median ± SD, minimum, and maximum). The normal distribution of data from each group was confirmed using the Kolmogorov-Smirnov normality test. Kruskal-Wallis test was employed to compare the groups for quantitative data. Mann-Whitney U test was used to detect the group causing the statistical difference and compare the data that did not show a normal distribution. The Friedman test was employed for intergroup comparisons of ABR data, while the Wilcoxon signed-ranks test was used for binary evaluation. P < 0.05 was considered statistically significant.
All the animals in the study and control groups subjected to ABR before treatment were observed to survive after treatment. The difference in weight loss between the study and control group animals was not statistically significant.
Ototoxicity was assessed by functional ABR measurements and histologically based on hair cell count. The pre-treatment ABR values were 13.95 ± 2.70 for the study group and 13.75 ± 2.91 for the control group (p = 0.755). At week 4, the ABR values were determined as 15.83 ± 1.94 and 13.75 ± 1.30 for the study and control groups, respectively, indicating a statistically significant difference (p = 0.014). At week 7, the ABR was found to be 15.00 ± 1.06 for the study group and 13.95 ± 1.67 for the control group (p = 0.630) (Table 1).
In the study group, the pre-treatment and week 4 ABR values of the study group did not statistically differ (p = 0.024). In the same group, the hearing loss did not significantly differ after treatment (at week 7) compared to day 0 based on ABR values (p = 0.157) (Table 2).
Light microscopy showed that outer hair cells were mostly protected in control groups. There was a slight loss of outer hair cell (Figure 1) and flattening of the organ of Corti (Figure 2) in the study group.
This study investigated the ototoxic effects of PD-1 inhibitor using histopathological and electrophysiological methods. According to the results of the study, PD-1 inhibitor caused hearing loss at the second dose of treatment; however, this was observed to be spontaneously resolved in the follow-up sessions. At the same time, the histopathological examination revealed a decrease in hair cells.
In recent years, immunotherapy drugs have been used for the treatment of many cancers. Cancer immunotherapy involves various therapeutic approaches that aim to boost the immune system and destroy tumor cells . However, since cancers are derived from the patient’s own cells, tumor cells retain many natural autoimmune defense mechanisms that can inhibit tumor immune destruction. Disruption of these autoimmune defense mechanisms has been shown to be highly successful in eliciting antitumor responses to many types of cancer. One of the well-known immune checkpoint pathways is PD-1 . Pembrolizumab, an approved IgG 4 monoclonal antibody for the treatment of advanced-stage melanoma and non-small cell lung cancer, also offers promising results in other malignancies . However, excessive accumulation of PD-1 antibodies in the liver and kidneys has limited the use of these agents in certain cases . Today, researchers are still seeking a solution to this problem, and the use of PD-1 inhibitor drugs in other cancers is increasing.
In the related literature studies, the effective dose of pembrolizumab was reported and accepted as 2 mg/kg. When pembrolizumab was administered at a dose of more than 2 mg/kg, there was only a minimal increase in drug activity . The half-life of pembrolizumab is 22 days; therefore, it is recommended that the drug be given in three-week periods . In the current study, we used pembrolizumab at the recommended dose of 2 mg/kg at three-week intervals to investigate the presence of ototoxic activity of pembrolizumab in clinical practice. When we review the literature, it has been reported that sensorineural hearing loss due to pembrolizumab use is usually bilateral, moderate-severe and hearing loss develops within the first three weeks after initiation of treatment [16, 17]. Therefore, the duration of our study was four weeks.
In a study by Spielbauer et al. using a murine model, the cisplatin-treated group was compared with the group that was administered cisplatin plus PD-1 inhibitor . Hearing loss was reported to be higher in the cisplatin plus PD-1 inhibitor group, but the difference between the two groups was not statistically significant. In the current study, although there was no significant difference in ABR between the study and control groups, we found that the hearing ability decreased in the study group. Furthermore, histopathologically, we found a decrease in hair cells in the inner ears of the rats in the study group compared to the control group. The data we obtained are consistent with those reported in the literature. We recommended that this study is repeated in human beings over a longer follow-up period.
It is also important to enumerate some of the limitations of this study. For example, the number of animals was limited. Furthermore, light microscopy is known to have limitations even when the best material is used and electron microscopy is essential to see the inner ear structures with much better resolution. Thus, further investigations using transmission and scanning electron microscopy methods are needed.
According to the data obtained from the rat model, pembrolizumab showed signs of ototoxicity during the course of the treatment, but hearing loss was spontaneously resolved during follow-up. The clinical significance of these findings should be confirmed by human studies. It is expected that in the future, otolaryngologists will see a large increase in the number of patients treated with chemoimmunotherapy. These patients should be monitored for hearing loss and other toxicities.
- Saba NF, Mody MD, Tan ES, et al.: Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); a new perspective in the era of immunotherapy. Crit Rev Oncol Hematol. 2017, 115:50-58. 10.1016/j.critrevonc.2017.04.011
- Baxi S, Yang A, Gennarelli RL, et al.: Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. BMJ. 2018, 360:k793. 10.1136/bmj.k793
- Mattox AK, Lee J, Westra WH, et al.: PD-1 expression in head and neck squamous cell carcinomas derives primarily from functionally anergic CD4(+) TILs in the presence of PD-L1(+) TAMs. Cancer Res. 2017, 77:6365-6374. 10.1158/0008-5472.CAN-16-3453
- England CG, Ehlerding EB, Hernandez R, et al.: Preclinical pharmacokinetics and biodistribution studies of 89Zr-labeled pembrolizumab. J Nucl Med. 2017, 58:162-168. 10.2967/jnumed.116.177857
- Sheth S, Weiss J: Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer. Future Oncol. 2018, 14:1547-1558. 10.2217/fon-2017-0628
- Zibelman M, Pollak N, Olszanski AJ: Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Immunother Cancer. 2016, 4:8. 10.1186/s40425-016-0114-4
- Nader ME, Myers JN, Gidley PW: Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis. J Immunother Cancer. 2017, 5:24. 10.1186/s40425-017-0226-5
- Lindauer A, Valiathan CR, Mehta K, Sriram V, de Greef R, Elassaiss‐Schaap J, de Alwis DP: Translational pharmacokinetic/pharmacodynamic modeling of tumor growth inhibition supports dose-range selection of the anti-PD-1 antibody pembrolizumab. CPT Pharmacometrics Syst Pharmacol. 2017, 6:11-20. 10.1002/psp4.12130
- Ozbay M, Sengul E, Kinis V, Alabalik U, Yilmaz B, Topcu I: Effects of caffeic acid phenethyl ester on cisplatin ototoxicity. B-ENT. 2016, 12:211-218.
- Breglio AM, Rusheen AE, Shide ED, et al.: Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 2017, 8:1654. 10.1038/s41467-017-01837-1
- Fujita T, Yamashita D, Katsunuma S, Hasegawa S, Tanimoto H, Nibu K: Increased inner ear susceptibility to noise injury in mice with streptozotocin-induced diabetes. Diabetes. 2012, 61:2980-2986. 10.2337/db11-1845
- Topalian SL, Taube JM, Anders RA, Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016, 16:275-287. 10.1038/nrc.2016.36
- Kyi C, Postow MA: Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014, 588:368-376. 10.1016/j.febslet.2013.10.015
- Dolan DE, Gupta S: PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014, 21:231-237. 10.1177/107327481402100308
- Khoja L, Butler MO, Kang SP, Ebbinghaus S, Joshua AM: Pembrolizumab. J Immunother Cancer. 2015, 3:36-45. 10.1186/s40425-015-0078-9
- Zibelman M, Pollak N, Olszanski AJ: Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab. J Otol Rhinol. 2016, 4:8. 10.1186/s40425-016-0114-4
- Hobelmann K, Fitzgerald D: A case of pembrolizumab induced autoimmune sensorineural hearing loss. J Otol Rhinol. 2019, 8:1.
- Spielbauer K, Cunningham L, Schmitt N: PD-1 inhibition minimally affects cisplatin-induced toxicities in a murine model. Otolaryngol Head Neck Surg. 2018, 159:343-346. 10.1177/0194599818767621
Investigation of the Ototoxic Effect of Pembrolizumab Using a Rat Model
Ethics Statement and Conflict of Interest Disclosures
Human subjects: All authors have confirmed that this study did not involve human participants or tissue. Animal subjects: Ankara Training and Research Hospital Issued protocol number 0046. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Cite this article as:
Kuzucu İ, Baklacı D, Guler İ, et al. (November 02, 2019) Investigation of the Ototoxic Effect of Pembrolizumab Using a Rat Model. Cureus 11(11): e6057. doi:10.7759/cureus.6057
Received by Cureus: October 28, 2019
Peer review began: October 29, 2019
Peer review concluded: October 29, 2019
Published: November 02, 2019
© Copyright 2019
Kuzucu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.